Fate Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Fate Therapeutics Inc 's ROA in the second quarter of 2026?
Fate Therapeutics Inc recorded a cumulative net loss of $-126 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -37.87%.

However, within the Healthcare sector 502 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3776, from total ROA ranking in the first quarter of 2026 at 4420.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	7.24 %	-24.47 %	-27.5 %	-27.1 %	-28.44 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-126	-130	-136	-156	-172
Return On Assets (TTM)	-37.87 %	-39.82 %	-39.02 %	-41.11 %	-41.66 %
FATE's Total Ranking	# 3776	# 4420	# 3904	# 3950	# 3985
Total Assets (TTM) in million	381	285	320	344	356
Seq. Total Assets Change	33.89 %	-11.08 %	-6.87 %	-3.29 %	-5.7 %
Seq. Net Income Change	-	-	-	-	-

FATE's 5 Years Annual ROA >> Back to FATE Management Effectiveness >> Compare FATE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 68
Sector	# 503
Overall	# 3777

Return On Assets Statistics
High	Average	Low
-21.39 %	-40.67 %	-69.83 %
(Dec 31 2021)		(Mar 31 2014)

Financial Statements
Fate Therapeutics Inc 's Assets	$ 381 million	FATE's Balance sheet
Fate Therapeutics Inc 's Income	$ -30 million	Quarterly FATE's Income Statement
FATE's Income by Division		See FATE's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-27.5 %	-12.86 %	-28.16 %	-23.38 %	48.04 %
Total Assets in million	320	442	507	706	921
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-136	-186	-161	-282	-212
Annual Return On Assets	-42.54 %	-42.15 %	-31.73 %	-39.9 %	-23.02 %

FATE's 5 Years Annual ROA >> Back to FATE Management Effectiveness >> Compare FATE ROA to its Competitors

More Return On Assets Ratios
FATE's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
FATE's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for FATE's Competitors
Subscribers only: Roa for Fate Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for FATE's Customers

You may also want to know
FATE's Roi	FATE's Inventory Turnover Ratio	FATE's Growth Rates	FATE's Dividend Comparisons
	FATE's Profitability Ratios	FATE's Asset Turnover Ratio	FATE's Dividend Growth
FATE's Roe	FATE's Valuation Ratios	FATE's Financial Strength Ratios	FATE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T11:45:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.